Health Research International Forecasts U.S. Peripheral Vascular Stent Market to Exceed $1.27 Billion in 2005.

Business & Health/Medical Editors

CLEVELAND--(BW HealthWire)--May 2, 2001

Faced with the growing maturity of coronary stenting applications, manufacturers are aggressively seeking opportunities for their stents outside of the heart.

Peripheral vascular disease, which presents primarily in the vessels of the neck, abdomen and limbs, affects an estimated 8 million people in the U.S. This caseload, coupled with new FDA product approvals, improved peripheral stent designs and expanded training of physicians in peripheral interventional techniques, will make peripheral vascular stenting the next major growth opportunity within the stent market. According to Health Research International (HRI), realization of this opportunity will produce a 19% annual increase in peripheral stent sales, from just under $550 million in 2000 to $1.27 billion in 2005.

"U.S. Market Opportunities for Peripheral Vascular Stents" is part of a new series offered by HRI that profiles strategic developments in U.S. Stent Markets. The report details approved peripheral vascular stenting technologies, such as stent-grafts for the endovascular treatment of abdominal aortic aneurysms, iliac artery stents and stents used for transjugular intrahepatic portosystemic shunts (TIPS). It also incorporates a thorough review of clinical and product developments and forecasts markets for important emerging applications, such as carotid, femoral/popliteal, and renal artery stenting -- including quantification of current off-label use of stents in these applications.

According to HRI Senior Research Analyst Michael Austriaco, "Assessing the various peripheral vascular stent markets represented an interesting challenge because so many of the applications lack FDA-approved products, and manufacturers are not at liberty to comment freely regarding off-label product use. To counterbalance this, our forecasts incorporate a detailed clinical assessment of these applications, obtained through extensive interviews with physicians and cath labs as well as a review of the medical literature, to arrive at a rational assessment of the specific market segments."

Companies whose technologies and strategies are detailed in this comprehensive report are: Biocompatibles International, Boston Scientific (BSX), Cook Group, C.R. Bard (BCR), Edwards Lifesciences (EW), Endologix, Endomed, Endotex, Guidant (GDT), Johnson & Johnson Cordis (JNJ), Jomed, Medtronic (MDT), Sulzer Medica/Sulzer Intratherapeutics (SM), Teramed, TriVascular, and W.L. Gore & Associates, among others.

The complete U.S. Stent Series encompasses more than 500 pages and 131 exhibits that present detailed market forecasts, analyses and company and product profiles. In addition to Peripheral Vascular Stents, other series reports cover: Coronary Stents, Antirestenosis Technologies, Urological Stents, and Peripheral Nonvascular Stents.

Founded in 1978, Health Research International (www.healthri.com) provides the pharmaceutical and medical device industries with reliable, comprehensive and meticulously researched market analysis that incorporates strategic vision and a thorough understanding of competing medical technologies. Quality, experience and follow through have been the cornerstones of our custom consulting business, which we are now expanding to include off-the-shelf market reports.